You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SARS-CoV-2-exposed subjects

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B

Not yet recruiting
  • SARS-CoV-2
  • +4 more
  • LumiraDx SARS-CoV-2 Ag Ultra
  • LumiraDx SARS-CoV-2 & Flu A/B
  • DeLand, Florida
    Hillcrest Medical Research
Feb 6, 2023

SARS-CoV-2 Infection Trial in Baltimore (Anti-SARS-CoV-2 Human Convalescent Plasma)

Completed
  • SARS-CoV-2 Infection
  • Anti-SARS-CoV-2 Human Convalescent Plasma
  • Baltimore, Maryland
    Johns Hopkins Hospitals
Dec 14, 2021

COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed Trial in United States (RQ-001, Placebo)

Recruiting
  • COVID-19
  • +3 more
  • RQ-001
  • Placebo
  • Cullman, Alabama
  • +8 more
Sep 28, 2023

Immunogenicity, Safety Trial (Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;)

Not yet recruiting
  • Immunogenicity
  • Safety
  • Phase II:SWIM816;SARS-Cov-2;
  • +3 more
  • (no location specified)
Jun 18, 2023

COVID-19 Trial in France (Hydroxychloroquine, Placebo of Hydroxychloroquine, Lopinavir and ritonavir)

Terminated
  • COVID-19
  • Angers, France
  • +8 more
Oct 3, 2022

Waxing and Waning of Serum SARS CoV-2-IgG Level in COVID-19

Recruiting
  • Covid19
  • Plasma IgG levels
  • Lahore, Punjab, Pakistan
  • +1 more
Feb 12, 2022

SARS-CoV-2, Prevention Trial in Chongqing (MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray, Placebo Comparator: MY-586

Recruiting
  • SARS-CoV-2
  • Prevention
  • MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray
  • Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient
  • Chongqing, Chongqing, China
    The Second Affiliated Hospital of Chongqing Medical University
Aug 2, 2023

SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Recombinant SARS-CoV-2 vaccine, Saline)

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Bivalent mRNA Vaccine
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023

SARS-CoV-2 Infection, Varicella, Measles Trial in Shanghai (Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine,

Not yet recruiting
  • SARS-CoV-2 Infection
  • +4 more
  • Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Municipal Center for Disease Control and Prevention
Jul 17, 2023

SARS-CoV-2 Virus Trial in Bangkok (SARS-CoV-2 RNA detection)

Completed
  • SARS-CoV-2 Virus
  • SARS-CoV-2 RNA detection
  • Bangkok, Thailand
    2 Division of Nephrology,Department of Medicine Pramongkutklao H
Aug 31, 2023

COVID-19 Trial in Wong Chuk Hang (SARS-CoV-2 DNA Vaccine (ICCOV))

Recruiting
  • COVID-19
  • SARS-CoV-2 DNA Vaccine (ICCOV)
  • Wong Chuk Hang, Hong Kong
    Gleneagles Hospital Hong Kong
Jun 16, 2023

SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Saline)

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Bivalent mRNA Vaccine
  • Saline
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023

SARS-CoV2 Infection Trial in Flint (General SARS-CoV-2 Communication, Rural-Targeted SARS-CoV-2 Communication)

Recruiting
  • SARS-CoV2 Infection
  • General SARS-CoV-2 Communication
  • Rural-Targeted SARS-CoV-2 Communication
  • Flint, Michigan
    Flint Journal Building
Oct 10, 2023

COVID-19 Trial in Guangzhou (the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine)

Recruiting
  • COVID-19
  • the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
  • Guangzhou, Guangzhou, China
    The Fifth Affiliated Hospital of Guangzhou Medical University
Jan 28, 2023

Sars-cov-2 on Donor Oocyte Quality and Quantity,Multicenter

Completed
  • Ovarian Reserve
  • +2 more
  • Sars Cov 2 infection
  • Sars Cov 2 vaccination
  • Bogotá, Colombia
    Novafem
Oct 3, 2022

COVID-19 Disease Trial in Berlin, Hamburg (ABNCoV2 100ug, ABNCoV2 50ug)

Active, not recruiting
  • COVID-19 Disease
  • ABNCoV2 100ug
  • ABNCoV2 50ug
  • Berlin, Germany
  • +1 more
Oct 21, 2022

SARS-CoV-2 Trial in Chengdu (SARS-CoV-2 mRNA vaccine (RBMRNA), CoronaVac®)

Active, not recruiting
  • SARS-CoV-2
  • SARS-CoV-2 mRNA vaccine (RBMRNA)
  • CoronaVac®
  • Chengdu, Sichuan, China
    Chengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023

Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in

Active, not recruiting
  • SARS-CoV-2 RNA Vaccines
  • HIV Infection
  • SARS-CoV-2 Vaccine
  • Sevilla, Spain
    Virgen del Rocio University Hospital
Dec 1, 2022

SARS-CoV-2 Trial in Newark (DUR-928, Placebo)

Terminated
Has Results
  • SARS-CoV-2
  • Newark, New Jersey
    Site 03
Jul 12, 2022

COVID-19 Trial (NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg))

Not yet recruiting
  • COVID-19
  • NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
  • Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
  • (no location specified)
Aug 4, 2023

SARS-CoV-2 Vaccination on Cancer Patients Infected With

Recruiting
  • COVID-19 Infection
  • COVID-19 Vaccine
  • no intervention
  • Beijing, Beijing, China
    Sanhuan Cancer Hospital, Chaoyang District, Beijing(Cancer Hospi
Mar 7, 2023

COVID-19: SARS-CoV-2-CZ-PREVAL-II Study

Completed
  • COVID-19
  • SARS-CoV-2 Infection
  • Quantitative analysis of SARS-CoV-2 antibodies
  • Cellular immunity
  • Prague, Czechia
    Institute of Health Information and Statistics of the Czech Repu
Nov 25, 2022

SARS-CoV-2 Trial in Chengdu (RBMRNA-176, Placebo)

Active, not recruiting
  • SARS-CoV-2
  • RBMRNA-176
  • Placebo
  • Chengdu, Sichuan, China
    Chengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023

SARS-CoV-2 Trial in Islamabad (SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution)

Recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
  • 0.9% sodium chloride solution
  • Islamabad, Pakistan
    Sindh Infectious Diseases Hospital & Research Center Dow Univers
Apr 16, 2023

Covid19 Trial in Cypress (VXA-CoV2-1)

Completed
  • Covid19
  • VXA-CoV2-1
  • Cypress, California
    WCCT
Jan 17, 2023